- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04020978
Parametric PET of Genitourinary Cancer
Pilot Study Using Parametric PET to Assess Early Treatment Response to Targeted Therapy for Genitourinary Cancer (GUC)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Renal cell carcinoma (RCC) is one of the top ten cancer types in the US. One-third of RCCs are metastatic and associated with a poor 5-year survival rate of 8%. Metastatic RCC is usually treated with targeted therapy or immunotherapy which is costly (>$10,000 per month) and has low response rate (<30%). Effective identification of the most appropriate drugs for a patient relies on noninvasive imaging to assess early response to the drugs. However, current practice by anatomical imaging such as computed tomography (CT) or magnetic resonance imaging (MRI) can only assess the response at two months after initialing targeted therapy. This approach exposes many patients to highly toxic, high expensive treatment without any benefit for months and delays initiation of other effective therapies.
The investigators hypothesize that functional perfusion imaging by positron emission tomography (PET) can enable RCC response assessment as early as at 1-2 weeks given that RCC is highly related to angiogenesis and most targeted drugs for RCC are antiangiogenic. However, clinical options for functional renal imaging are very limited. While dynamic contrast-enhanced CT or MRI can be used for perfusion imaging, their use is restricted because 30% of RCC patients have chronic kidney diseases with renal dysfunction and are at higher risk for contrast-induced nephropathy and nephrogenic systemic fibrosis. Existing PET radiotracers (e.g., 15O-water) for perfusion imaging are short-lived and generally unavailable for clinical use. This project explores parametric PET perfusion imaging using the widely accessible 18F-fluorodeoxyglucose (FDG). 18F-FDG PET is conventionally used for metabolic imaging and has been rarely used for imaging kidneys because physiological excretion of 18F-FDG into renal pelvis contaminates image quality for renal tumor assessment. The investigators explore the potential of the metabolic radiotracer 18F-FDG for perfusion imaging by employing four-dimensional (4D: 3D space plus 1D time) dynamic scanning and tracer kinetic modeling, leading to parametric imaging of FDG perfusion kinetics without being affected by 18F-FDG excretion. The parametric PET method can potentially identify RCC response and assess drug efficacy with 1-2 weeks of treatment as compared to 2 months by current anatomical imaging methods.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Lynda Painting, BS
- Phone Number: 916-731-9004
- Email: lpainting@ucdavis.edu
Study Contact Backup
- Name: Dana Little, MS
- Phone Number: 916-734-7749
- Email: dalittle@ucdavis.edu
Study Locations
-
-
California
-
Sacramento, California, United States, 95817
- UC Davis Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with pathologically confirmed GUC. For those patients whose primary kidney cancer is removed, they must have index metastatic cancer lesion(s) within the PET field of view for 18F-FDG parametric PET/CT analysis to determine response.
- Patients are scheduled for targeted cancer therapy, including sunitinib, pazopanib, cabozantinib, everolimus, and others.
- Ability to understand and willingness to sign an informed consent form.
- Ability to adhere to the study visit schedule and other protocol requirements.
- Men and women ≥21 years of age.
- Life expectancy ≥ 6months.
- Female subjects who are of non-reproductive potential (i.e., post-menopausal by history - no menses for ≥1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy). Or, female subjects of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the first drug administration.
- Male and female subjects who agree to use highly effective method of birth control (e.g., implants, injectables, birth control pills with two hormones, intrauterine devices [IUDs], complete abstinence or sterilized partner, and female sterilization) and a barrier method (e.g., condoms, vaginal ring, sponge, etc.) during the period of therapy and for 90 days after the last dose of drug.
- For the minority cohort, subject must be a member of a Federally recognized racial/ethnic minority population to include: African Americans or Black; Native American; Alaska Native; Native Hawaiian or other Pacific Islander; Asian American; Hispanic or Latino. This will be verified through self-reporting by the subject.
Exclusion Criteria:
- Pregnant or lactating women.
- Any condition that would prohibit the understanding or rendering of informed consent.
- Any medical condition including additional malignancies, laboratory abnormalities, or psychiatric illness that would prevent the subject from participating and adhering to study related procedures.
- Prior treatment with any investigational drug within the previous 4 weeks
- Unable to lie supine for 1-hour imaging with PET
- Prisoners
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Patients with GUC
Each patient with GUC will first undergo an X-ray CT scan for attenuation correction purpose.
After that, 10 mCi 18F-Fludeoxyglucose (18F-FDG) will be injected into the patient through the IV in a period of 10 seconds.
The PET scan commences 10 seconds before the FDG injection and lasts for 60 minutes.
After the PET scan, the patient gets off the scanner.
One blood sample (10cc) will be drawn using a butterfly method with the time recorded.
|
Each patient will undergo a dynamic F18-FDG PET/CT scan at baseline and 2-week post therapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in blood flow
Time Frame: Two weeks
|
Tumor blood flow in the unit of mL/min/g will be derived from early-dynamic FDG-PET with tracer kinetic modeling.
The change between baseline and follow-up scans will be calculated.
|
Two weeks
|
Changes in blood volume
Time Frame: Two weeks
|
Tumor blood volume fraction in percentage will be derived from early-dynamic FDG-PET with tracer kinetic modeling.
The change between baseline and follow-up scans will be calculated.
|
Two weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation with tumor anatomical response
Time Frame: Two months
|
Correlation between the functional changes measured by parametric PET/CT at two weeks with anatomical size change measured by standard CT or MRI at two months.
|
Two months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Inclusion of Minority Cohort
Time Frame: One year after treatment
|
Inclusion of subjects of various race and/or ethnicity to ensure findings can be generalizable to the entire population and to gather information about differences by race and/or ethnicity.
|
One year after treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Guobao Wang, PhD, University of California, Davis
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1374902
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Genitourinary Cancer
-
Duke UniversityWallace H. Coulter FoundationCompletedCancer of the Gastrointestinal, Genitourinary or Gynecologic SystemsUnited States
-
National Yang Ming UniversityNational Science Council, TaiwanCompletedGenitourinary Symptoms
-
Duke UniversityArgos TherapeuticsTerminatedMetastatic Renal Cell Carcinoma | Genitourinary Cancer (Bladder, Prostate or Testicular)United States
-
Żelazna Medical Centre, LLCLaboratory of Genetics and Human Genomics, University of GdańskCompleted
-
National Cancer Institute (NCI)WithdrawnBreast Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Endocrine/Neuroendocrine | Gastrointestinal/Genitourinary CancersUnited States
-
Dana-Farber Cancer InstituteCompletedKidney Cancer | Prostate Cancer | Genitourinary CancerUnited States
-
Samsung Medical CenterCompletedGenitourinary Cancer | Metastatic Gastrointestinal CancerKorea, Republic of
-
IGF Oncology, LLCCompletedMelanoma | Breast Cancer | Brain Cancer | Head and Neck Cancers | Gastrointestinal Cancers | Gynecologic Cancers | Genitourinary Cancers | Thoracic CancersUnited States
-
Samsung Medical CenterCompletedGastric CancerKorea, Republic of
-
59th Medical WingCompletedGenitourinary SymptomsUnited States
Clinical Trials on Parametric PET/CT
-
Aarhus University HospitalCompletedPositron-Emission TomographyDenmark
-
Sun Yat-sen UniversityUnknownNasopharyngeal CarcinomaChina
-
Peter MacCallum Cancer Centre, AustraliaMelbourne Health; Westmead Hospital; Victorian Infectious Diseases Reference...CompletedAcute Myeloid Leukemia | Febrile Neutropenia | Acute Lymphoblastic Leukemia | Haematopoietic Stem Cell Transplant, Autologous | Haematopoietic Stem Cell Transplant, AllogeneicAustralia
-
HALO DiagnosticsCompletedProstate CancerUnited States
-
Massachusetts General HospitalNational Cancer Institute (NCI)Completed
-
Washington University School of MedicineTerminatedCervical Cancer | Uterine Cervical Neoplasms | Uterine Cervical CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedMalignant Neoplasm of Breast TNM Staging Distant Metastasis (M) | Untreated Bone MetastasesUnited States
-
University of UtahNational Cancer Institute (NCI)CompletedFluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) in Cancer Associated VenothromboembolismVenothromboembolismUnited States
-
The Catholic University of KoreaUnknownNon-small Cell Lung CancerKorea, Republic of
-
Peking Union Medical College HospitalRecruitingClear Cell Renal Cell CarcinomaChina